Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients

Background. Hydroxychloroquine with or without azithromycin was one of the common therapies at the beginning of the COVID-19 pandemic. They can prolong QT interval, cause torsade de pointes, and lead to sudden cardiac death. We aimed to assess QT interval prolongation and its risk factors in patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Seyed Parsa Eftekhar, Sohrab Kazemi, Mohammad Barary, Mostafa Javanian, Soheil Ebrahimpour, Naghmeh Ziaei
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Cardiovascular Therapeutics
Online Access:http://dx.doi.org/10.1155/2021/6683098
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832550942460870656
author Seyed Parsa Eftekhar
Sohrab Kazemi
Mohammad Barary
Mostafa Javanian
Soheil Ebrahimpour
Naghmeh Ziaei
author_facet Seyed Parsa Eftekhar
Sohrab Kazemi
Mohammad Barary
Mostafa Javanian
Soheil Ebrahimpour
Naghmeh Ziaei
author_sort Seyed Parsa Eftekhar
collection DOAJ
description Background. Hydroxychloroquine with or without azithromycin was one of the common therapies at the beginning of the COVID-19 pandemic. They can prolong QT interval, cause torsade de pointes, and lead to sudden cardiac death. We aimed to assess QT interval prolongation and its risk factors in patients who received hydroxychloroquine with or without azithromycin. Methods. This study was a retrospective cohort study. One hundred seventy-two confirmed COVID-19 patients were included in this study, hospitalized at Babol University of Medical Sciences hospitals between March 5, 2020, and April 3, 2020. Patients were divided into two groups: hydroxychloroquine alone and hydroxychloroquine with azithromycin. Electrocardiograms were used for outcome assessment. Results. 83.1% of patients received hydroxychloroquine plus azithromycin vs. 16.9% of patients who received only hydroxychloroquine. The mean age of patients was 59.2±15.4.The mean of posttreatment QTc interval in the monotherapy group was shorter than the mean of posttreatment QTc interval in the combination therapy group, but it had no significant statistical difference (462.5±43.1 milliseconds vs. 464.3±59.1 milliseconds; p=0.488). Generally, 22.1% of patients had a prolonged QTc interval after treatment. Male gender, or baseline QTc≥450 milliseconds, or high-risk Tisdale score increased the likelihood of prolonged QTc interval. Due to QTc prolongation, fourteen patients did not continue therapy after four days. Conclusions. Hospitalized patients treated by hydroxychloroquine with or without azithromycin had no significant difference in prolongation of QT interval and outcome. The numbers of patients with prolonged QT intervals in this study emphasize careful cardiac monitoring during therapy, especially in high-risk patients.
format Article
id doaj-art-e0d20340568a4d21bcc5275111224169
institution Kabale University
issn 1755-5914
1755-5922
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series Cardiovascular Therapeutics
spelling doaj-art-e0d20340568a4d21bcc52751112241692025-02-03T06:05:27ZengWileyCardiovascular Therapeutics1755-59141755-59222021-01-01202110.1155/2021/66830986683098Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed PatientsSeyed Parsa Eftekhar0Sohrab Kazemi1Mohammad Barary2Mostafa Javanian3Soheil Ebrahimpour4Naghmeh Ziaei5Student Research Committee, Health Research Center, Babol University of Medical Sciences, Babol, IranCellular and Molecular Biology Research Center, Health Research Center, Babol University of Medical Sciences, Babol, IranStudent Research Committee, Health Research Center, Babol University of Medical Sciences, Babol, IranInfectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, IranInfectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, IranDepartment of Cardiology, Babol University of Medical Sciences, Babol, IranBackground. Hydroxychloroquine with or without azithromycin was one of the common therapies at the beginning of the COVID-19 pandemic. They can prolong QT interval, cause torsade de pointes, and lead to sudden cardiac death. We aimed to assess QT interval prolongation and its risk factors in patients who received hydroxychloroquine with or without azithromycin. Methods. This study was a retrospective cohort study. One hundred seventy-two confirmed COVID-19 patients were included in this study, hospitalized at Babol University of Medical Sciences hospitals between March 5, 2020, and April 3, 2020. Patients were divided into two groups: hydroxychloroquine alone and hydroxychloroquine with azithromycin. Electrocardiograms were used for outcome assessment. Results. 83.1% of patients received hydroxychloroquine plus azithromycin vs. 16.9% of patients who received only hydroxychloroquine. The mean age of patients was 59.2±15.4.The mean of posttreatment QTc interval in the monotherapy group was shorter than the mean of posttreatment QTc interval in the combination therapy group, but it had no significant statistical difference (462.5±43.1 milliseconds vs. 464.3±59.1 milliseconds; p=0.488). Generally, 22.1% of patients had a prolonged QTc interval after treatment. Male gender, or baseline QTc≥450 milliseconds, or high-risk Tisdale score increased the likelihood of prolonged QTc interval. Due to QTc prolongation, fourteen patients did not continue therapy after four days. Conclusions. Hospitalized patients treated by hydroxychloroquine with or without azithromycin had no significant difference in prolongation of QT interval and outcome. The numbers of patients with prolonged QT intervals in this study emphasize careful cardiac monitoring during therapy, especially in high-risk patients.http://dx.doi.org/10.1155/2021/6683098
spellingShingle Seyed Parsa Eftekhar
Sohrab Kazemi
Mohammad Barary
Mostafa Javanian
Soheil Ebrahimpour
Naghmeh Ziaei
Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients
Cardiovascular Therapeutics
title Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients
title_full Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients
title_fullStr Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients
title_full_unstemmed Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients
title_short Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients
title_sort effect of hydroxychloroquine and azithromycin on qt interval prolongation and other cardiac arrhythmias in covid 19 confirmed patients
url http://dx.doi.org/10.1155/2021/6683098
work_keys_str_mv AT seyedparsaeftekhar effectofhydroxychloroquineandazithromycinonqtintervalprolongationandothercardiacarrhythmiasincovid19confirmedpatients
AT sohrabkazemi effectofhydroxychloroquineandazithromycinonqtintervalprolongationandothercardiacarrhythmiasincovid19confirmedpatients
AT mohammadbarary effectofhydroxychloroquineandazithromycinonqtintervalprolongationandothercardiacarrhythmiasincovid19confirmedpatients
AT mostafajavanian effectofhydroxychloroquineandazithromycinonqtintervalprolongationandothercardiacarrhythmiasincovid19confirmedpatients
AT soheilebrahimpour effectofhydroxychloroquineandazithromycinonqtintervalprolongationandothercardiacarrhythmiasincovid19confirmedpatients
AT naghmehziaei effectofhydroxychloroquineandazithromycinonqtintervalprolongationandothercardiacarrhythmiasincovid19confirmedpatients